BTIG Rates Monopar Therapeutics (MNPR) buy, $117 Price Target
BTIG maintains its buy rating for Monopar Therapeutics Inc., setting a $117 price target, a 26.36% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
BTIG rated Monopar Therapeutics Inc. ($MNPR) "buy" with a $117 price target on June 30, 2026.
Since the rating, $MNPR is up 2.8% after 1 week, up 23.8% after 1 month and down 25.2% to date (from the $92.59 close on Jun 30, 2026).
MNPR
Monopar Therapeutics Inc.
Key Points
- BTIG reiterated its buy rating for Monopar Therapeutics Inc. (MNPR) on June 30, 2026, with a price target of $117.
- BTIG's $117 price target implies 26.36% upside from Monopar Therapeutics Inc.'s ($MNPR) current $92.59 share price.
- Shares of Monopar Therapeutics traded near $94.56 on Wednesday, with a market cap of approximately $620 million.
- Monopar Therapeutics has a strong buy consensus with a mean target price of $112.62 among 13 analysts.
Get $MNPR trade alerts by text
We text you when insiders, Congress or big funds trade $MNPR. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Monopar Therapeutics Inc. alert may contain errors. Disclosures
BTIG analyst Jeet Mukherjee reiterated a buy rating for Monopar Therapeutics Inc. (NasdaqCM: MNPR) on June 30, 2026. The firm set a price target of $117 for the biopharmaceutical company. Monopar's shares traded around $94.56 on Wednesday.
BTIG vs. the S&P 500
Hypothetical returns from BTIG's disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in Monopar Therapeutics
Several institutional investors have shown varied interest in Monopar Therapeutics. Saturn V Capital Management LP increased its holdings by 19,925 shares, reaching a total of 345,626 shares valued at about $18.9 million, marking a 6.1% increase. Deerfield Management Company, L.P. added 153,187 shares, boosting its stake by 89.8% to 323,745 shares worth approximately $17.7 million. Meanwhile, BlackRock, Inc. raised its position by 61,710 shares, a 24.2% increase, resulting in 316,567 shares valued at $17.3 million. In contrast, Adage Capital Partners GP, L.L.C. reduced its stake by 330,272 shares, a 51.6% decrease, ending with 309,195 shares worth about $16.9 million.
Monopar Therapeutics Inc. Stock Down 4.0%
As of Wednesday, shares of Monopar Therapeutics Inc. (NasdaqCM: MNPR) traded near $94.56. The company has a market capitalization of roughly $620 million. Monopar's stock has experienced a 52-week range between $29.18 and $105.00. The stock's 50-day moving average is $62.52, and the 200-day moving average is $67.90. Monopar has a beta of 1.539, indicating a higher volatility compared to the market.
$MNPR price target
Monopar Therapeutics Inc. daily closes and this analyst's $117 target. Not advice.
Analysts Set New Price Targets
On June 30, 2026, BTIG maintained its buy rating for Monopar Therapeutics with a $117 price target. The day before, HC Wainwright & Co. reiterated its buy rating with a target of $105. Overall, the consensus among analysts is a strong buy, with a mean price target of $112.62 based on 13 analyst opinions.
About Monopar Therapeutics Inc.
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company based in Wilmette, Illinois. It focuses on developing cancer treatments, including ALXN1840, a potential therapy for Wilson disease, and MNPR-101, a monoclonal antibody for advanced tumors. Founded in 2014, Monopar collaborates with various partners to advance its pipeline. The company is led by Dr. Chandler D. Robinson and employs 22 people.
Bottom Line
BTIG's reiteration of a buy rating for Monopar Therapeutics Inc. reflects continued confidence in the company's prospects. Investors closely watch such analyst ratings as they provide insights into potential stock performance. As always, it's important to remember that these ratings are based on past data and may not reflect current market conditions.
Related Filing Alerts
Source: BTIG's rating change on $MNPR (Jun 30, 2026). Written by software, not financial advice. How we make alerts